肿瘤防治研究2024，Vol.51Issue(7)：606-612,7.DOI:10.3971/j.issn.1000-8578.2024.23.1373
抗体-药物偶联物毒性的发生机制与优化方法研究进展
Research Progress on Mechanisms and Optimization Methods for Toxicity Induced by Antibody-Drug Conjugates
摘要
Abstract
Since the approval of gemtuzumab ozogamicin,an antibody-drug conjugate(ADC)targeting CD33 in 2000,13 ADC drugs have been approved by the FDA.Although these drugs have clearly improved the survival of patients with various types of advanced cancers,their significant toxicity has compromised their therapeutic benefits.The adverse reactions of ADC drugs are complex and include on-target and off-target toxicities,where the payload drug is a determining factor.Antibody and linker may also affect the degree of toxicity.Combination therapy becomes an important strategy in anticancer treatment because of its increased efficiency,but treatment-related adverse reactions also increase accordingly.This review comprehensively analyzes the toxicity mechanisms of current ADC drugs and proposes various optimization strategies,including but not limited to optimizing linker molecules,upgrading antibody design,and changing drug administration strategies,to improve the overall safety profile of ADC drugs.关键词
抗体-药物偶联物/靶向治疗/毒性/优化策略Key words
Antibody-drug conjugates/Targeted therapy/Toxicity/Optimization strategies分类
医药卫生引用本文复制引用
贾艳丽,李小钰,范厚武,段文清,胡丽霞,周健,冉凤鸣,董爽..抗体-药物偶联物毒性的发生机制与优化方法研究进展[J].肿瘤防治研究,2024,51(7):606-612,7.基金项目
Wuhan Knowledge Innovation Foundation(No.2023020201010175) 武汉市知识创新基金(2023020201010175) （No.2023020201010175）
